Compare TLRY & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLRY | MDXG |
|---|---|---|
| Founded | N/A | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 625.6M |
| IPO Year | 2018 | 2007 |
| Metric | TLRY | MDXG |
|---|---|---|
| Price | $4.03 | $4.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $72.33 | $9.00 |
| AVG Volume (30 Days) | ★ 3.1M | 951.4K |
| Earning Date | 04-01-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.69 | 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | $8.79 | N/A |
| Revenue Next Year | $19.98 | $13.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $0.77 | $3.03 |
| 52 Week High | $15.70 | $7.97 |
| Indicator | TLRY | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 41.49 | 54.19 |
| Support Level | $3.87 | $4.11 |
| Resistance Level | $4.91 | $4.76 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 31.18 | 45.76 |
Tilray is as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. The company portfolio includes brand such as Sweet Water Brewing, Montauk Brewing, Brew Dog, Shock Top, 10 Barrell, Breckenridge Brewery, Blue Point Brewing, Breckenridge Distillery, Revolver, Terrapin, Broken Coast, Good Supply, Redecan, Solei, Tilray, ARX, XMG, Manitoba Harvest and Hi-Ball. The company has four segment Beverage, Cannabis, Distribution and Wellness. The majority of the revenue is generated from Distribution business which encompasses the purchase and resale of pharmaceuticals products to customers.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.